HYPOGONADISM IN THE PRADER-WILLI SYNDROME FROM BIRTH TO ADULTHOOD – A 28-YEAR EXPERIENCE IN A SINGLE CENTRE

1Sakina Kherra, 2Wendy Forsyth Paterson, 3Filiz Mine Cizmecioglu, 4Jeremy Huw Jones 5Mariam Kourime, 6Heba Hassan Elsedfy, 7Sameh Tawfik Amer, 4Andreas Kyriakou, 4Mohammed Guftar Shaikh, 8Malcolm David Cairns Donaldson

1CHU Parnet Hopital, Algiers, Algeria 2Deceased, previously Royal Hospital for Sick Children, Yorkhill, Glasgow, UK, 3Kocaeli University, Paediatric Endocrinology & Diabetes Department, Turkey 4Department of Pediatric Endocrinology, Royal Hospital for Children Glasgow, NHS Greater Glasgow and Clyde, Glasgow G51 4TF, UK, 5Abderrahim Harouchi Hôpital, Casablanca, Morocco, 6Pediatrics Department, Ain Shams University, Cairo, Egypt, 7Department of Pediatrics, Maadi Hospital, Cairo, Egypt, 8Section of Child Health, Glasgow University School of Medicine, Glasgow G12 8QQ, UK.

Corresponding author: Dr M Donaldson, Section of Child Health, Royal Hospital for Children, Glasgow G51 4TF, Scotland, UK.

Email: malcolm.donaldson@glasgow.ac.uk

Short title: Hypogonadism in the Prader-Willi syndrome

Key words: Prader-Willi syndrome, central hypogonadism, primary hypogonadism, cryptorchidism, orchidopexy, pelvic ultrasound, gonadotrophins, human chorionic gonadotrophin, puberty, estrogen therapy, testosterone therapy

Word count 4613

Tables: 5

Figures: 4

Supplementary figures: 4

References: 34
ABSTRACT

**Background:** Hypogonadism is a key feature of Prader-Willi syndrome (PWS) but clear strategies for hormone replacement are lacking. **Objective:** To evaluate gonadal status and outcome in patients attending a Scottish PWS clinic from 1991-2019. **Methods:** In 93 (35F:56M) patients, median follow-up 11.2 years, gonadal and pubertal status were assessed clinically. Pelvic ultrasound findings and basal/stimulated gonadotrophins were compared with age-matched controls. **Results:** Females: Of 22 patients aged >11, 9 had reached B4-5, while 5 were still at B2-3, and 6 remained prepubertal. Eight patients experienced menarche aged 9.8-21.4 years, none with a normal cycle. Uterine length and ovarian volumes were normal but uterine configuration remained immature, with low follicular counts. Gonadotrophins were unremarkable, serum estradiol 129 (70 – 520) pmol/L. Only 5 patients received oestrogen replacement. Males: Fifty-four (96%) patients were cryptorchid (9 unilateral). Weekly hCG injections resulted in unilateral/bilateral descent in 2/1 of 25 patients. Of 37 boys aged >11, 14 (9 with failed/untreated bilateral cryptorchidism) failed to progress beyond G1, 15 arrested at G2-3 (testes 3-10 ml), and 8 reached G4-5. Gonadotrophins were unremarkable except in boys at G2-5 in whom FSH was elevated: 12.3/27.3 vs 3.25/6.26 U/L in controls (p<0.001). In males aged >13, testosterone was 3.1 (0.5-8.4) nmol/L. Androgen therapy, given from 13.5-29.2 years, was stopped in 4/24 patients owing to behavioural problems. **Conclusion:** Despite invariable hypogonadism, few females and only half the males with PWS in this study received hormone replacement. Double-blind placebo-controlled crossover trials of sex steroids are required to address unproven behavioural concerns (250 words)
INTRODUCTION

The Prader-Willi syndrome (PWS) results from absence of paternally imprinted genes in the 15q 11-13 region, caused by deletion in the paternal chromosome (del15q) in 70% of cases and disomy of the maternal chromosome (mUPD15) in about 25% [1]. Rarer causes include imprinting centre mutations (2), and unbalanced translocation/deletions involving the critical region of 15q (3).

PWS is a neurodevelopmental disorder with particular impact on the hypothalamus. Key features include hypotonia, hyperphagic obesity, mild-to-moderate learning disability, major behaviour difficulties, impaired linear growth, and hypogonadism (4-6). Full independent living in adulthood is precluded by the behaviour difficulties and hyperphagia which, when unchecked, results in morbid obesity with type 2 diabetes, and death from respiratory failure and skin sepsis (5,6).

The profile of hypogonadism in PWS males has been well documented (7-12). Clinical features include small penis, scrotal hypoplasia and cryptorchidism at birth, with spontaneous puberty but mid-pubertal arrest, and reduced testicular volume attributable to a reduction in seminiferous tubules. Basal gonadotrophins and testosterone levels during early childhood are unremarkable, with preservation of mini-puberty (13), but inhibin B levels wane from 10 years onwards (7-9). Testosterone levels are low during and after puberty, and basal FSH is elevated in some but not all pubertal and adult patients (7-10). Testicular histology in adults is variable (10) with no reports of male fertility.

Fewer centres have reported on females with hypogonadism (8,11,14,15). Features include hypoplastic labia at birth, normal age of pubertal onset but delayed although usually complete secondary sexual development and invariable oligo-amenorrhoea. Longitudinal basal gonadotrophin, anti-Müllerian hormone (AMH) and Inhibin B from birth to adulthood are
usually within the population range, but oestradiol levels during and after puberty are low (15).

For three decades, we have held a multidisciplinary PWS clinic in Glasgow (5), using pelvic ultrasonography, gonadotrophin stimulation testing and human chorionic gonadotrophin (hCG) stimulation in the assessment of our patients, whose mean duration of follow up is nearly 15 years. The purpose of this paper is to report on outcome in our patients, and discuss optimal management of hypogonadism, including cryptorchidism and sex hormone replacement therapy.

PATIENTS AND METHODS

At the inception of the Glasgow PWS clinic in 1991, focus was initially on diagnosis, separating PWS patients from those with other causes of learning disability and obesity by using the Holm criteria (4) combined with newly established methylation testing techniques for 15 q analysis (16).

Until 2011, clinical, biochemical, pelvic ultrasound and surgical treatment details on PWS patients were collected on a rolling basis by our auxologist, Wendy Paterson, who also logged information on patients attending the hospital between 1974 and 1991. After her untimely death in 2012, data collection was relaunched in 2015 and finalized in 2019.

Pubertal staging was carried out according to the method of Tanner (17) and menstrual history recorded. Staging in girls and women was carried out mainly by WFP from 1991-2011, or by our specialist endocrine nurse from 1995 until the end of the study period.

Testicular position and volume were assessed both clinically and from surgical operation notes.

A pelvic ultrasound service was established in 1990, with normative data established in girls aged ≤15 years (18). Transabdominal pelvic ultrasound examination was performed using an Acuson 128 XP10 system (Mountain View, CA, USA) with a 5- or 7-MHz sector probe.
Uterine length and ovarian volumes were plotted onto normative centile charts. The number and size of ovarian follicles between 2-10 mm diameter, and the number measuring >10 mm was recorded. Uterine shape was classified as infantile (cervix wider than fundus), cylindrical (cervical and fundal depth approximately equal), or pubertal (fundal depth >cervical depth) and also expressed as the fundal-cervical ratio (FCR). Uterine length in older patients was compared with the normative data for nulliparous women aged 25 years (19). Endometrial thickness was recorded, and the values detected compared with the normative data of Gilligan et al [20].

Luteinising hormone (LH) and follicle stimulating hormone (FSH) were measured using an Abbott AxSYM from 1990 until 2004, by DPC Immulite 2000 (Siemens) until 2014 and Abbott Architect immunoassay thereafter. Testosterone and Estradiol were measured at Glasgow Royal Infirmary, by radioimmunoassay until 2013 and since then by liquid chromatography–mass spectrometry (LC-MS). In 2000, Inhibin B was measured in male patients in a single batch run using a double antibody enzyme-linked immunosorbent assay (ELISA), as previously described (21). Inhibin B in females, and sex hormone binding globulin (SHBG) and Anti-Mullerian hormone (AMH) in both sexes were not measured sufficiently regularly to be analysed in this study.

Assay detection limits for LH and FSH were <0.5 U/L until 2010, <0.1 from 2010 to 2014, and <0.2 from 2015. Detection limits were <0.5 nmol/L for Testosterone, <70 pmol/L for Estradiol and 8 ng/L for Inhibin B. Gonadotrophin stimulation tests were performed using 100 ug of LHRH (Relefact LH-RH-Hoechst Marion Rousse) and peak LH and FSH values at 30 and 60 minutes recorded. Stimulation tests were always carried out between 9 a.m. and 11 a.m. but basal hormone measurements taken in clinic could be either in the morning or afternoon.
Normative data from 85 subjects undergoing investigation by the same laboratory, usually for short stature and delayed puberty, in whom no endocrine abnormality was found are shown in Table 1 and are used for comparison.

hCG (Profassi (Serono) or Pregnyl (Organon)) was given as a single intramuscular injection (usually 5,000 units), or for 4-5 days (usually 1,500-2,000 units) to test Leydig cell reserve from 1982-1995. Thereafter, it was largely superseded by twice weekly hCG, usually 1500-2000 units, for 3-6 weeks to promote testicular descent.

**Data analysis**

Biochemical data are presented according to specified age bands, using one data point per patient per age band. In patients with more than one point per age band, data were selected from the age closest to the mid-point, with priority given to pelvic ultrasound measurements in which the ovaries had been visualised, and in biochemical tests where an LHRH test had been carried out. For statistical purposes, gonadotrophin values of <0.2 or <0.5 U/L were evaluated as if at the limit of detection.

All statistical analyses were done using Minitab (version 19) at a significance level of 5% for data sets where n=5 or greater. Data distribution was assessed for normality using Anderson-Darling test. Parametric data are presented as mean (±SD) and non-parametric data as median (range) or median (range). Quantitative variables were compared using t-tests and ANOVA or Kruskal-Wallis and Mann-Whitney tests, as appropriate. Qualitative variables were compared using chi-squared or Fisher’s exact tests.

**Ethical aspects**

Approval was initially granted by the Ethical Committee of the Royal Hospital for Sick Children in Glasgow in 2004 and data collection initially completed in 2011. The second phase of the study was approved by the NHS Research Ethics Authority (reference 15/NW/0900). In 2019, the current status of patients, where available, was assessed via
Clinical Portal (https://www.ggc-clinicalportal.scot.nhs.uk/concerto). Consent was obtained from each patient and family after full explanation of the purpose and nature of all procedures used.

RESULTS

Between 1991 and 2019 a total of 93 patients (37 females, 56 males), born between 1950 and 2016, were seen in the multidisciplinary PWS clinic (Table 2). Deaths were recorded in 11 patients (3 female), 9 with complications of morbid obesity aged 26 (17.8-40) years, while a woman died unexpectedly at 44 years with pneumonia, and a boy aged 14.4 years died with complications of extra-hepatic portal hypertension which were unrelated to PWS. Ten patients were lost to follow-up. Death rates before and after excluding the 10 patients lost for follow-up were 11/93 (11.8%) and 11/83 (13.2%). After excluding 15 patients seen on fewer than three occasions, mean duration of follow-up was 14.8 years. Neonatal details of the cohort have already been presented elsewhere (22). Mean birthweight was significantly reduced at 2.69 kg (n=87) compared to 3.33-3.4 kg for the Scottish population from 1980-2003).

Peak growth hormone levels were 4.9 (0.03-26.0) μg/L (n=31), with 8 and 11 values <3 and 3-7 μg/L respectively. Growth hormone treatment was given to 20/55 patients born before the year 2000 and to 22/38 born from 2000 onwards. No patient received thyroxine. Obesity status at the most recent visit is shown in Table 2. Fourteen patients had developed type 2 diabetes, the youngest from 14 years. Significant psychiatric problems had been recorded in 22 (31%) of the 72 patients who were aged 13 years by the end of the study.

Gonadal status - females

Clinical features
Hypoplastic labia majora was poorly documented, being recorded in six of only 12 patients examined. Ages at reaching B2 and B5 were 12.2 (7.2-14.8) (n=13), and 16.1 (14.6-8.4) (n=7) years. Two girls showed early breast development including one aged 7.2 years with B2 development, prepubertal LHRH test and pelvic ultrasound and a second with true puberty at 9.8 years - Tanner stage B3P2A2, menarche and basal/peak LH 4.2/32.8 U/L.

Of 28 patients aged ≥11 years at last review, 9 women were at B4-5, four still B3 (aged 13.8-21.8 years), three still B2 (aged 12.4 -13.6 years), 6 still B1 (aged 11 - 17.5 years), no data in 6. Spontaneous menarche had been recorded in 8 patients (two at B3, six at B5) aged 17 (9.8-21.4) years, with no menses in 13, of whom two were below 13 years and 11 were 17.1 (13.8 - 46.8) years at last review, no data in 7. No patient had a normal cycle, with only one recorded period in two, and ≤4 periods/year in the remaining patients.

**Pelvic ultrasound findings (see Figures 1a-c and Table 3)**

Table 3 and Figures 1a-c show the uterine and ovarian parameters in 16 patients undergoing pelvic ultrasound examination. Uterine length fell within normal centiles in all but 2 of 20 measurements from 12 patients aged 2-16 years, while in women aged >20 years the values were consistent with the mean value of 67 mm in normal nulliparous women aged 25 years (19). However, a pubertal uterine configuration was found in only 2 girls aged <15 years, 2/9 patients aged 15 – 20 years and 3/5 aged >20 years. FCR remained ≤1 in 11/26 measurements in 11 patients aged >15 years, compared with >1 in all normal Scottish girls by this age (18). Endometrial thickness was detected in 15 of 44 examinations in 14 patients aged ≥11 years, median (range) 1 (1-4.6) mm.

Ovarian volumes up to 15 years were within the normative Griffin et al centiles with one exception (Figures 1b and 1c), with mean ovarian volumes 1.95 ml (B1), 3.3 (B2-3) and 5.3 ml (B4-5) similar to normative data. However, the maximum count of follicles measuring 2-
10 mm never exceeded 6 at any age (see Table 3) while follicles of >10 mm were seen in only three patients.

**Biochemistry (see Table 4 and Supplementary figures SF1a and b)**

Basal LH was at or below the limit of detection for 13/20 patients aged 2-4.9 and 5-10.9 years, with no difference between mean basal and stimulated LH between patients and controls at B1.

Basal FSH was always detectable in patients aged 2-4.9 years, but at or below the limit of detection in 5/14 patients aged 5-10.9 years. Mean basal and peak FSH were significantly lower in the 5-10.9 age band than controls: 1.3 (1.46) vs 2.2 (0.89) U/L (p=0.03); 5.98 (1.58) vs 12.7 (3.65) U/L (p=0.001). After 11 years no significant differences were found, either for subjects still at B1, or at B2-5. Basal FSH was <10 U/L in all but two patients: 14.1 U/L in a 46.8-year-old woman; and basal/peak 11.4/51.2 U/L in a girl aged 2.1 years. Estradiol values were undetectable in all but 2 patients aged <11 years. In patients aged 11-20 years, estradiol was undetectable in three, median (range) 129 (70 – 520) pmol/L in 16.

**Treatment**

Two patients received a single course of Norethisterone, 5 mg daily for five days, for breakthrough bleeding. A further two received monthly Norethisterone for 4 and 15 months before starting estrogen treatment.

By the end of the study period, only five of the 24 patients with primary amenorrhoea aged >14 years had been treated with estrogen: one with estradiol valerate + medroxyprogesterone as a 3-monthly cycle, one with Loestrin 20 (ethinylestradiol 20 mcg and norethisterone 1 mg) aged 19.5 years (stopped after 6 months owing to weight gain), one with ethinyl estradiol from 17.4 to 22.4 years, another with ethinyl estradiol from 16.4 years followed by Loestrin 20 at 24 years, and one with oestradiol valerate 1 mg from 17.9 years.

**Gonadal status – males (see Figure 2)**
Clinical features

Unstretched penile length at birth was recorded in 23/56 boys as: <2 cm (n=3), 2.1-3 cm (n=17) and >3 cm (n=3). One or both testes were undescended in 54 patients (bilateral in 45), with normal descent in 2. Initial position of the left/right testis was documented as abdominal (n=8/6), inguinal canal (n=11/9), external inguinal ring (n=8/7), scrotal (n=2/2), not specified (n=17/22).

Forty-four patients underwent orchidopexy, mean (SD) age at first surgery being 8.8 (5.6) years (n = 24) prior to 2000, and 2.0 (0.7) years from 2000-2016 (n = 15). Of the remaining patients, one underwent bilateral orchidectomy elsewhere aged 19.7 years, four older patients were never operated on, surgery was pending in one, surgery not required in three, no information available in one.

Of 25 patients receiving twice-weekly hCG courses, only three showed testicular descent - bilateral descent from the inguinal position after 1000 units for 4 weeks in one boy (post-hCG testosterone unavailable); and unilateral descent from inguinal and external ring in two patients receiving 1000 units for three weeks (post-hCG testosterone 21.8 nmol/L and unavailable respectively).

Figure 2 shows that orchidopexy was successful in 31 patients (8 unilateral), unsuccessful in 7 (2 unilateral) and partially successful in 8 (one viable testis brought into scrotum). The boys with failed bilateral orchidopexy were born between 1978 and 1987, age at operation ranging between 4 and 16 years, testes abdominal in 2, not documented in 3. After unsuccessful surgery at 4 years, one patient had undergone laparotomy-assisted left and right orchidopexy at 14.1 and 15 years but both testes then became atrophic. Of the boys with unsuccessful surgery in one testis, atrophy/absence was present at surgery in 6 and atrophy occurred following 1st and 2nd stage Fowler Stephen’s procedures in two.

Pubertal development (see Figure 2)
Data were available in 37 boys aged >11 years on 1st January 2020. Fourteen boys had not progressed beyond G1 prior to receiving treatment, or death. While this was expected in the cases of orchidectomy (1) and failed/no orchidopexy (9), four patients had not progressed despite having either both (n=2) or one (n=2) viable testes in the scrotum. Age at G2 was 12.7 (10.2 - 15.6) years (n=10). Four boys remained at G2 with 4-8 mL testes at the last recorded visit, including one of the boys with unilateral testicular descent post-hCG. Age at spontaneous G3 was 13.4 (10.3 – 17.7) years (n=14). Eleven patients did not progress beyond G3, testicular volumes 6 (3-10) mL, including two with unilateral cryptorchidism and two with normally descended testes (one post-hCG). Eight patients reached spontaneous G4 (n=3), and G5 (n=5) at 15.7 (13.0-18.16) years, testicular volumes 6 (4-15) mL, including three who had had unsuccessful surgery in one testis. At last review, 7 patients aged >11 years were still at G1, three at G2, 14 (10 treated) at G3, 8 (7 treated) at G4 and 7 (3 treated) at G5. Testicular volumes in the 15 patients at G4 or G5 ranged between absent (n=4), 1-2 mL (n=1), 3-4 mL (n=6), 5-6 mL (n=6), 8-10 mL (n=5) and 12 mL (n=3) (no data for 5 testes). Pubic hair stage for patients at G4 and G5 was P4 (n=3), P5 (n=8), no data (n=4).

Biochemistry (Table 5, Supplementary Figure SF2a and b)

LH and FSH data

At <2 years, LH and FSH responses to GnRH appeared normal. From 2-10.9 years basal and stimulated gonadotrophins were lower cf controls, but not significantly.

For patients aged ≥11 years who were still at G1, and after excluding the anorchic patient, mean basal/peak gonadotrophins were not different from controls: 0.9/3.5 (n=18/12) v 0.4/3.1 (n=13) (p=0.12) for LH and 2.3/3.1 vs 0.6/2.4 (p=0.36) for FSH.
For patients at G2-5, basal and stimulated LH levels were non-significantly higher than controls: 2.43/25.4 (n=23/6) vs 1.49/14.4 (n=14/14). However, FSH values were significantly higher: 12.3/27.3 vs 3.25/6.26 (p<0.001)

**hCG, Testosterone and Inhibin B data**

Twelve patients, all born before 1986, received 15 hCG treatments by daily injection over 4 (1-5) days in the dose of 5,000 (50-6,000) units at 13.9 (6.3-18.6) years. After excluding tests from 3 patients who showed no response - two with severe hypogonadism (both failing to progress subsequently beyond G1) and one in whom non-response was considered spurious (patient subsequently progressing to G5), median (range) post-hCG testosterone was 7.7 (1.9-26.8) nmol/L.

Twenty-three patients received 24 hCG treatments as twice-weekly injections, duration 6 (2-6) weeks, dose 1500 (500 – 2000) at a significantly younger age - 7 (0.4- 19.8) years (10 patients aged < 2 years) (p=0.038). After excluding two patients (one spurious non-response and one of the patients with severe hypogonadism) post-hCG testosterone lower than with daily injections at 19 (12.92) 12 (5.7 – 41.5) nmol/L (n=11) but the difference did not reach significance (p=0.06).

Peak testosterone after hCG in subjects aged <2 years was consistent with intact Leydig cell function (see Table 5). However, basal testosterone at G3-5 was 3.1 [0.5-8.4] nmol/L (n=15), well below the adult reference range of 8-37.5 nmol/L.

Inhibin B values, measured in 15 patients, were all recordable (>10 pg/mL), but below the age-related reference ranges in all but one boy aged 7.2 years (Table 5). Inhibin B values did not correlate with either basal FSH or Tanner stage, being no different in boys with FSH <0.6 vs 1-12 U/L or pubertal stage G1 vs G2-5. There was also no correlation between Inhibin B and testicular volumes, for example 13.3- 70 pmol/L in three prepubertal boys with 2 ml testes, and 14.7-63.3 in 7 boys with testes 5-6 ml.
**Treatment (see Figure 2)**

Of 46 patients aged >13 years on 1st January 2020, 24 had started testosterone therapy aged 16.8 (13.5-29.2) years, 19 had received no treatment, no information in three. All but two of the treated patients had been treated with combined testosterone esters, given as Sustanon, initial dose 50-62.5 mg (n=16) and 100 mg (n=15) every 6 weeks (n=14); and maximal dose 50-62.5 mg (n=2), 100 (n=9), 125 mg (n=3) and 200-250 mg (n=8) every 2 (n=2), 4 (n=9), 6 (n=11) and 12 (n=1) weeks. Recent treatment details were not available in all patients aged >16 years who were under adult follow-up. Electronic clinical records indicated that treatment had been stopped in four due to behavioural concerns.

**DISCUSSION**

This series spans a 45-year period, the earliest patients being seen from 1974, thus providing valuable longitudinal information including previously unpublished pelvic ultrasound data. There is however the disadvantage of incomplete patient data and, intrinsic to a study of this nature, inconsistent protocols and management. Specifically, the study period conceals trends in clinical practice including reduction in age at diagnosis and first surgery, differing hCG regimens, and increased use of GH. Hormone assays varied during the study period, with relatively insensitive gonadotrophin cut-offs until 2014. Another methodological variable was breast staging in female patients. Distinguishing between true breast development and adipose tissue in females with and without PWS can be difficult. While stage 4 and 5 breast development were diagnosed with confidence by our dedicated auxologist and specialist nurse, distinction between B1, B2 and B3 in obese patients was, unavoidably, a matter of subjective (albeit expert) judgement.

In females, the clinical profile is of partial hypogonadism, most but not all girls entering puberty spontaneously, less than half achieving full adult breast development, and primary or oligo-amenorrhea in all.
In this study, we present pelvic ultrasound in PWS for the first time. This method is well-established in paediatrics for assessing and measuring uterine shape and configuration–indices of estrogen secretion; and ovarian volume and follicular number and size - indices of gonadotrophin stimulation.

We found that uterine length was normal up to the age of 16 (see Figure 1a), but the mature, ‘pear-shaped’ configuration seen in normal Scottish girls by 15 years (18) was usually not achieved (see Table 3). Endometrial thickness, another index of estrogen secretion, was usually not detected in patients over 11 years, with a median value of only 1 mm, well below the normative mean of 4.5±3.7 mm (19).

Gonadotrophin secretion was sufficient to result in normal ovarian volumes (see Figures 1b and c), but not the normal antral follicle counts of 6.2-33.2 reported in healthy 16-year-olds by transvaginal ultrasound examination (23). The gonadotrophin profile was unremarkable, apart from slightly lower FSH levels in the 5-10.9 age group. Estradiol levels were reduced from adolescence onwards, values never >600 pmol/L in patients aged >15 years. These data are consistent with previous reports (8,11,15,).

In males, the clinical profile is again consistent with previous work (7-12). Small penile size at birth is common but micropenis rare (8,13), and cryptorchidism almost constant. Outcome after orchidopexy was inferior compared with the general population, partly attributable to pre-existing hypoplasia/atrophy (24). Untreated or failed bilateral cryptorchidism resulted in pubertal failure. However, males with failed unilateral orchidopexy but a contralateral testis in place fared as well at puberty as those with bilateral descent (see below). Thus, if one viable testis is in the scrotum in PWS, extensive efforts to salvage a problematic testis with re-do orchidopexy appear unjustified.

Preoperative weekly hCG treatment was relatively unsuccessful in our experience, with descent in only 4/46 (8%) testes versus 4/29 (14%) in the study of Bakker et al study (25).
Further study using internationally agreed protocols is required to define the role of hCG administration in PWS, regarding both scrotal descent and improving outcome in intra-abdominal cryptorchidism.

Apart from the boys with failed/untreated cryptorchidism, a small number of patients remained at G1 despite successful unilateral or bilateral orchidopexy. Boys who entered puberty spontaneously all had reduced testicular volumes, most showing mid-pubertal arrest as previously reported (4,7,13) but some reaching G4/5. The reduction in testicular volume seen in PWS is attributable to reduced seminiferous tubule tissue (10), demonstrable in subjects as young as 2 years (25). Of note, neither spontaneous/hCG-induced testicular descent seemed to protect against mid-pubertal arrest, three boys arresting at G2-3 comprising two with normally descended testes (one post-hCG) and one with unilateral descent post-hCG. By contrast, three boys who reached G4/5 had only one testis successfully treated.

The biochemical profile was of normal basal and stimulated gonadotrophins and testosterone response to hCG between 0-2 years, in keeping with intact minipuberty (10, 13). Gonadotrophins were unremarkable in prepubertal boys. Figure S2b shows the well-described FSH elevation seen from adolescence (7-12) but this was confined to boys showing spontaneous puberty. Testosterone levels were subnormal from adolescence onwards while Inhibin B in a relatively small cross section of patients was almost uniformly low. Testosterone data post-hCG treatment were variable but an adequate or good response was usual on both daily and weekly regimes. The higher mean testosterone levels in patients receiving weekly rather than daily hCG, might reflect the greater response to prolonged stimulation but could also be explained by greater Leydig responsiveness in younger subjects. Possible mechanisms for the hypogonadism in PWS are the subject of debate. Hypogonadotrophic hypogonadism would seem the most likely explanation, given the known
hypothalamic dysfunction in PWS. However, basal gonadotrophin levels in infancy and childhood are usually unremarkable in both sexes, even with cut-offs as sensitive as <0.1 U/L (9,15). This could reflect the limited ability of basal/stimulated gonadotrophin measurement in detecting dysregulation of hypothalamic GnRH secretion. Detection of primary hypogonadism also poses problems. Raised FSH levels are only informative when hypothalamo-pituitary function is sufficiently intact and not when a concurrent central defect is present. Inhibin B has been used as an indicator of gonadal impairment in PWS (7,8,9,12,26) but low inhibin B levels are also found in hypogonadotrophic hypogonadism affecting both sexes (27,28). The failure in our study to correlate Inhibin B levels with FSH, Tanner stage or testicular volume may reflect its limitations in separating the effect of central, peripheral or combined hypogonadism.

In female PWS, the pattern of normal ovarian volumes, normal AMH (14, 15) but low follicular count is evocative of central hypogonadism in childhood and adolescence. However, an accompanying peripheral defect cannot be excluded in our female cohort, and it is likely that the unrecordable Inhibin B levels (<10 pg/mL) reported in older PWS females do reflect primary gonadal impairment (26).

In males, hypogonadotrophic hypogonadism is suggested by cryptorchism with smallish penis at birth, non-elevated gonadotrophins, and the failure of some patients to enter puberty spontaneously. An additional primary defect is also evident from FSH elevation in pubertal males, and from the known histological abnormalities (10,24).

Given that hypogonadism is invariable in PWS, it is paradoxical that no clear treatment guidelines have been developed. In our series, some but not all boys received a variety of regimes, usually in the form of 4-6 weekly intramuscular testosterone, on an individual basis. The underlying reasons for such undertreatment reflect the wider health concerns over PWS
which include death from morbid obesity, and the fear of sex steroid replacement exacerbating existing behavioural problems.

Regarding the concern over obesity, our study shows the significant mortality in PWS and that, consistent with data from France (29) and the United states (30), almost all the adult deaths were obesity-related, with a median age of 26 years. However, in contrast to the French study (29) only two deaths in our series occurred in patients aged below 18 years, with no deaths recorded in patients under two years – a discrepancy which could reflect problems with ascertainment since our earliest patients were born in the 1970s when some subjects with PWS could have died undiagnosed. However, there are no data to show that appropriate sex steroid replacement therapy exacerbates morbid obesity in PWS.

Regarding the risk of sex steroid exacerbating behaviour problems in PWS, the comprehensive review of Noordam et al points to the lack of scientific evidence for any detrimental (31). Of 27 males described by these authors, all 7 in whom androgen replacement was discontinued for behavioural reasons had pre-existing problems.

Accordingly, the authors recommend inducing puberty at the normal dose and the normal age in PWS, administering estradiol 0.5 mg daily from 11-12 years in girls, and testosterone enanthate 100mg/4 weeks from 13 – 14.5 years in boys (31).

Furthermore, it is important to consider the potential benefits, not only of growth hormone replacement therapy (32), but also sex steroid replacement therapy on metabolic health and body composition in PWS (33). Kido et al, in an adult study of 22 PWS males given 125 mg of intramuscular testosterone monthly for two years showed improvement in body fat, lean muscle mass and bone mineral density with no change in Modified Overt Aggression Scale (MOAS) behaviour scores (33). It is therefore possible that sex hormone replacement might actually reduce the risk of obesity-related death in PWS. Moreover, sex hormone replacement
could positively influence behaviour, mental health and quality of life in PWS, as has been shown with transdermal testosterone therapy in hypogonadal men (34).

We believe that the question of sex steroid treatment and its effect on behaviour in PWS should be resolved by randomised, placebo-controlled crossover studies. Given the ethical and practical concerns of giving intramuscular placebo injections, we advocate studies examining oral or transdermal testosterone and oestrogen replacement. This approach, when combined parental recording the severity and frequency of behavioural events would provide the evidence needed to inform future management.

Declaration of interest

The authors declare no conflict of interest.

Funding

None

Acknowledgements

The authors wish to honour the memory of Ms Wendy Paterson, who recorded the clinical, biochemical and pelvic ultrasound data for this study until her untimely death in 2012. Without her faithful and painstaking work, we would have been unable to publish the results of this long-term study. The authors also gratefully acknowledge the generous help and advice given by Professor Tim Cole, Professor Richard Anderson, Professor Regis Coutant, Dr Jane McNeilly and Dr Peter Galloway. We thank Mr Hamish Donaldson for assisting with data analysis, and Mr Mark Whittington for preparing the Figures. Finally, we pay tribute to the patients and families with PWS who have attended the Glasgow clinic.

REFERENCES

1. Cassidy SB, Schwartz S, Miller JL & Driscoll DJ. Prader-Willi syndrome. Genetics in Medicine 2012 14 10-26.
2. Buiting K, Saitoh S, Gross S, Dittrich B, Schwartz S, Nicholls RD & Horsthemke B. Inherited microdeletions in the Angelman and Prader-Willi syndromes define an
imprinting centre on human chromosome 15. *Nat Genet* 1995 9 395-400. Erratum in: *Nat Genet* 1995 10 249. PubMed PMID: 7795645.

3. Charrow J, Balkin N & Cohen M. Translocations in Prader-Willi syndrome. *Clin Genet* 1983 23 304-7 doi: 10.1111/j.1399-0004.1983.tb01881.x.

4. Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY & Greenberg F. Prader-Willi syndrome: Consensus diagnostic criteria. *Pediatrics* 1993 91 398-402.

5. Donaldson MDC, Chu CE, Cooke A, Wilson A, Greene SA & Stephenson JBP. The Prader-Willi syndrome. *Arch Dis Child* 1994 70 58-63.

6. Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC & Tauber M. Speakers contributors at the Second Expert Meeting of the Comprehensive Care of Patients with PWS. Recommendations for the diagnosis and management of Prader-Willi syndrome. *J Clin Endocrinol Metab* 2008 93 4183–4197.

7. Eiholzer U, l’Allemand D, Rousson V, Schlumpf M, Gasser T, Girard J, Gruters A & Simoni M. Hypothalamic and gonadal components of hypogonadism in boys with Prader-Labhart-Willi syndrome. *J Clin Endocrinol Metab* 2006 91 892–898.

8. Hirsch HJ, Eldar-Geva T, Bennaroch F, Pollak Y & Gross-Tsur V. Sexual dichotomy of gonadal function in Prader-Willi syndrome from early infancy through the fourth decade. *Hum Reprod* 2015 30 2587-2596.

9. Siemensma EP, de Lind van Wijngaarden RF, Otten BJ, de Jong FH & Hokken-Koelega AC. Testicular failure in boys with Prader-Willi syndrome: longitudinal studies of reproductive hormones. *J Clin Endocrinol Metab*. 2012 97 E452-9. doi: 10.1210/jc.2011-1954. Epub 2011 Dec 21.

10. Matsuyama S, Matsui F, Matsuoka K, Iijima M, Takeuchi M, Ida S, Matsumoto
F & Mizokami A. Gonadal function and testicular histology in males with Prader-Willi syndrome. *Endocrinol Diabetes Metab* 2018 30 e00049. doi: 10.1002/edm2.49.

11. Crino A, Schiaffini R, Ciampalini P, Spera S, Beccaria L, Benzi F, Bosio L, Corrias A, Gargantini L, Salvatoni A, et al. Genetic Obesity Study Group of Italian Society of Pediatric Endocrinology and Diabetology (SIEDP). Hypogonadism and pubertal development in Prader-Willi syndrome. *Eur J Pediatr*. 2003 162 327-333.

12. Radicioni A, Di Giorgio G, Grugni G, Cuttini M, Losacco V, Anzuini A, Spera S, Marzano C, Lenzi A, Cappa M & Crino A. Multiple forms of hypogonadism of central, peripheral or combined origin in males with Prader-Willi syndrome. *Clin Endocrinol (Oxf)* 2012 76 72–77 doi: 10.1111/j.1365-2265.2011.04161.x

13. Fillion M, Deal CL & Van Vliet G. Normal minipuberty of infancy in boys with Prader-Willi syndrome. *J Pediatr*. 2006 149 874-876.

14. Eldar-Geva T, Hirsch HJ, Benarroch F, Rubinstein O & Gross-Tsur V. Hypogonadism in females with Prader-Willi syndrome from infancy to adulthood: variable combinations of a primary gonadal defect and hypothalamic dysfunction. *Eur J Endocrinol* 2010 162 377-84. doi: 10.1530/EJE-09-0901. Epub 2009 Nov 27.

15. Siemensma EP, van Alfen-van der Velden AAEM, Otten BJ, Laven JS & Hokken-Koelega AC. Ovarian Function and Reproductive Hormone Levels in Girls with Prader-Willi Syndrome: A Longitudinal Study. *J Clin Endocrinol Metab* 2012, 97, E1766–E1773. [doi.org/10.1210/jc.2012-1595](doi.org/10.1210/jc.2012-1595)

16. Chu C E, Cooke A, Stephenson J B P, Tolmie J L, Clarke B, Parry-Jones W L, Connor J M & Donaldson M D C. Diagnosis in Prader-Willi syndrome. *Arch Dis Child* 1994 71 441-442.

17. Tanner JM. *Growth at Adolescence, 2nd edn*. Oxford: Blackwell Scientific.
18. Griffin IJ, Cole TJ, Duncan KA, Hollman AS & Donaldson MDC. Pelvic ultrasound measurements in normal girls. *Acta Paediatrica Scandinavica* 1995 **84** 536-43.

19. Verguts J, Ameve L, Bourne T & Timmerman D. Normative data for uterine size according to age and gravidity and possible role of the classical golden ratio. *Ultrasound in Obstetrics and Gynecology* 2013 https://doi.org/10.1002/uog.12538

20. Gilligan LA, Trout AT, Schuster JG, Schwartz BI, Breech LL, Zhang B & Towbin AJ. Normative values for ultrasound measurements of the female pelvic organs throughout childhood and adolescence. *Pediatr Radiol* 2019;49(8):1042-1050. doi: 10.1007/s00247-019-04419-z.

21. Crofton PM, Evans AEM, Groome NP, Taylor MRH, Holland CV & Kelnar CJH. Dimeric inhibins in girls from birth to adulthood: relationship with age, pubertal stage, FSH and oestradiol. *Clin Endocrinol* 2002 **56** 223-230

22. Çizmecioğlu FM, Jones JH, Paterson WF, Kherra S, Kourime M, McGowan R, Shaikh MG & Donaldson M. Neonatal Features of the Prader-Willi Syndrome; The Case for Making the Diagnosis During the First Week of Life. *J Clin Res Pediatr Endocrinol*. 2018 **10** 264-273. doi: 10.4274/jcrpe.0029.

23. La Marca A, Spada E, Sighinolfi G, Argento C, Tirelli A, Giuliani S, Milani S & Volpe A. Age-specific nomogram for the decline in antral follicle count throughout the reproductive period. *Fertil Steril* 2010 DOI: 10.1016/j.fertnstert.2010.07.1069

24. Pacilli M, Heloury Y, O’Brien M, Lionti T, Rowell M & Hutson J. Orchidopexy in children with Prader-Willi syndrome: Results of a long-term follow-up study. *J Pediatr Urol* 2018 **14** 63.e1-63.e6. doi: 10.1016/j.jpurol.2017.10.003
25. Bakker NE, Wolffenbuttel KP, Looijenga LH & Hokken-Koelega AC. Testes in infants with Prader-Willi syndrome: human chorionic gonadotropin treatment, surgery and histology. *J Urol* 2015 193 291e8.

26. Gross-Tur V, Hirsch HJ, Benarroch F & Eldar-Geva T. The FSH-inhibin axis in Prader-Willi syndrome: heterogeneity of gonadal dysfunction. *Reprod Biol Endocrinol.* 2012 10 39. doi: 10.1186/1477-7827-10-39

27. Corvest V, Lemaire P, Brailly-Tabard S & Brauner R. Puberty and Inhibin B in 35 Adolescents With Pituitary Stalk Interruption Syndrome. *Front. Pediatr.* 2020 https://doi.org/10.3389/fped.2020.00304

28. Coutant R, Biette-Demeneix E, Bouvattier C, Bouhours-Nouet N, Gatelais F, Dufresne S, Rouleau S & Lahlou N. Baseline inhibin B and anti-Mullerian hormone measurements for diagnosis of hypogonadotropic hypogonadism (HH) in boys with delayed puberty. *J Clin Endocrinol Metab* 2010 95 5225-5232 doi.org/10.1210/jc.2010-1535

29. Alfaro DLP, Lemoine P, Ehlinger V, Molinas C, Diene G, Valette M, Pinto G, Coupaye M, Poitou-Bernert C, Thuilleaux D, Arnaud C & Tauber M. Causes of death in Prader-Willi syndrome: lessons from 11 years’ experience of a national reference center. *Orphanet Journal of Rare Diseases* 2019 14:238 doi.org/10.1186/s13023-019-1214-2

30. Butler MG, Manzardo AM, Heinemann J, Loker C & Loker J. Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genetics in Medicine 2017;19:635-642

31. Noordam C, Höybye C & Eiholzer U. Prader–Willi Syndrome and Hypogonadism: A Review Article. Int J of Mol Sci 2021 2021, 22, 2705. doi.org/10.3390/ijms22052705
32. Damen L, Grootjen LN, Donze SH, Juriaans AF de Graaff LCG, van der Velden JAEM & Hokken-Koelega ACS. Three years of growth hormone treatment in young adults with Prader-Willi Syndrome previously treated with growth hormone in childhood: Effects on glucose homeostasis and metabolic syndrome. Clinical Endocrinology 2020;93(4): 439-448. https://doi.org/10.1111/cen.14274

33. Kido Y, Sakazume S, Abe Y, Oto Y, Itabashi H, Shiraishi M, Yoshino A, Tanaka Y, Obata K, Murakami N et al. Testosterone Replacement Therapy to Improve Secondary Sexual Characteristics and Body Composition Without Adverse Behavioral Problems in Adult Male Patients with Prader-Willi Syndrome: An Observational Study. Am J Med Genet 2013;161 (9): 2167–2173. doi.org/10.1002/ajmg.a.36048

34. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T & Berman N, Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition in hypogonadal men. J Clin Endocrinol Metab 2000 85 2839–2853.

**Legend to Figures**

Figure 1a, b and c: Uterine length (1a), left ovarian volume (1b) and right ovarian volume (1c) in 16 females with Prader-Willi syndrome undergoing pelvic ultrasound examination, colour-coded according to breast stage: B1 = ●, B2 = ○, B3 = ●, B4 = ●, B5 = ●, and plotted onto the normative centile charts of Griffin et al (13).

Figure 2. Gonadal status in 56 males with Prader-Willi syndrome in relation to initial testicular position, response to treatment with human chorionic gonadotrophin (hCG),
outcome after surgery (if performed), maximum spontaneous genital (G) stage of puberty aged $\geq 11$ years, and status regarding initial testosterone replacement.

For hCG treatment, $n=$ refers to number of boys receiving pre-operative weekly hCG. $(n=)$ refers to boys aged <11 years at time of last clinic visit.

Abbreviations: Orch = orchidectomy, N/K = not known, U = unsuccessful orchidopexy, P = partially successful orchidopexy (one viable testis in scrotum), S = successful orchidopexy, I.M. = intramuscular.

Supplementary Figure SF1a and b: Data points for LH (luteinising hormone) (SF1a) and FSH (follicle-stimulating hormone) (SF 1b) at baseline (LH0 & FSH0), 30 minutes (LH30) and 60 minutes (FSH 60) after stimulation with GnRH in females with Prader-Willi syndrome grouped according to age band, and compared with normative data (see Table 1). Breast stage for PWS females is colour-coded as: B1 = ●, B2 = ●, B3 = ●, B4 = ●, B5 = ●; and for comparison girls as B1 = ●, B2-5 = ●

Supplementary Figure SF 2a and b: Data points for LH (luteinising hormone) (SF 2a) and FSH (follicle-stimulating hormone) (SF 2b) at baseline (LH0 & FSH0), 30 minutes (LH30) and 60 minutes (FSH 60) after stimulation with GnRH in males with Prader-Willi syndrome grouped according to age band, and compared with normative data (see Table 1). Genital stage for PWS males is colour-coded as: G1 = ●, G2 = ●, G3 = ●, G4 = ●, G5 = ●; and for comparison boys as G1 = ●, G2-5 = ●
Table 1. Reference data for gonadotrophins from the Department of Biochemistry, Royal Hospital for Sick Children, Glasgow before (basal) and after (peak) stimulation with 100 mg intravenous LHRH, derived from 85 subjects, aged 3–17 years, with no evidence of endocrine disease. Reference data for serum testosterone and estradiol are from the Institute of Biochemistry, Glasgow Royal Infirmary.

| Tanner stage | Basal LH U/L | Peak LH U/L | Basal FSH U/L | Peak FSH U/L | Testosterone nmol/L | Estradiol pmol/L |
|--------------|--------------|-------------|---------------|--------------|---------------------|-----------------|
| **Girls**    |              |             |               |              |                     |                 |
| B1 (n=21)    | 0.5 [0.2-2.4]| 1.95 [0.5-4.7]| 2.0 [0.2-5]   | 11.6 [2.2-26.4]|                     |                 |
| B2 (n=4)     | 0.5 [1.3-2.6]| 8.9 [1.4-12.5]| 3.7 [0.5-8.9] | 13.15 [6.8-22.2]|                     |                 |
| B3-5 (n=5)   | 1.0 [0.7-1.8]| 14.3 [6.1-31.9]| 5.5 [1.7-6.9]| 13.8 [7-15.6]   | 70 [40-300]        |                 |
| **Boys**     |              |             |               |              |                     |                 |
| G1 (n=43)    | 0.5 [0.2-1]  | 1.6 [0.5-8.8] | 0.85 [0.2-3.4]| 4.4 [0.9-11.6]  | 0.4 [0.3-1.3]      |                 |
| G2 (n=9)     | 0.8 [<0.2-2]| 8.1 [3.3-13.6]| 1.7 [0.3-4.2] | 2.6 [0.9-11.2] | 0.9 [0.7-11.2]     |                 |
| G3-5 (n=6)   | 1.9 [1.9-4]  | 22.3 [16.4-27.2]| 3.2 [1.8-10.6]| 6.45 [2.8-17]   | 13.2 [8.3-17.2]   |                 |
| **Adult**    |              |             |               |              | 8.7-35              | 180-1500        |

LH = luteinising hormone, FSH = follicle stimulating hormone, LHRH = luteinising hormone releasing hormone, B = breast stage, G = genital stage of puberty according to Tanner.
Table 2. Background information on 93 patients with Prader-Willi syndrome (PWS) seen at the Glasgow clinic between 1991 and 2019. Median (minimum – maximum) values are given with number of patients (n=). See text for information on growth hormone status and treatment.

|                                | Females  | Males    | All patients |
|--------------------------------|----------|----------|--------------|
| Number of patients             | 37       | 56       | 93           |
| Birth year (range)             | 1950 – 2014 | 1969-2016 | 1950 – 2016  |
| Died                           | 4        | 7        | 11           |
| Lost to follow up              | 2        | 8        | 10           |
| Age on 1st January 2020        | 15.6 (5.2-50.3) | 21.8 (3.1-49.8) | 19.3 (3.1 – 50.3) |
| (excluding deaths and patients lost to follow up) | n= 31 | n=41 | n=72 |
| median (range) duration of follow-up | 10.4 (4.3-36.8) | 12 (1.2-40.8) | 11.2 (1.2-40.8) |
| (excluding 15 patients seen ≤3 occasions) | n=32 | n=46 | n=78 |
| Cause of PWS (n=88)            |          |          |              |
| Deletion                       | 27       | 29       | 56           |
| Disomy (unspecified)           | 2        | 6        | 8            |
| Heterodisomy                   | 3        | 13       | 16           |
| Isodisomy                      | 4        | 0        | 4            |
| Imprinting defect              | 0        | 2        | 2            |
| Translocation                  | 0        | 1        | 1            |
| No defect found                | 1        | 0        | 1            |
| Tested elsewhere               | 4        | 1        | 5            |
| Birthweight (kilograms)        | 2.72 (1.58-3.93) | 2.76 (0.87-3.99) | 2.69 (0.87-3.99) |
| n=36                           | n=51     | n=87     |              |
| Gestation (weeks)              | 38.5 (33-43) | 39 (27-43) | 39 (27-43) |
| n=36                           | n=53     | n=89     |              |
| Obesity status at last review (n=87) |          |          |              |
| Non obese (BMI <91st centile)  | 12       | 14       | 26           |
| Overweight (BMI 91st-98th centile) | 6       | 6        | 12           |
| Obese (BMI >98th centile)      | 10       | 14       | 24 (3 died)  |
| Morbidly obese (BMI >40 kg/m²) | 8        | 17       | 25 (8 died)  |
| Psychiatric problems recorded in patients >13 years (n=72) |          |          |              |
| Anxiety/obsessive compulsive   | 3        | 3        | 6            |
| Depression                     | 2        | 1        | 3            |
| Psychosis/bipolar disorder     | 1        | 2        | 3            |
| Marked aggression              | 2        | 7        | 9            |
| Antisocial behaviour towards animals |        | 1        | 1            |
Table 3. Pelvic ultrasound findings, showing one point per patient per age band. Median (minimum – maximum) values are given with number of patients (n=). See reference 17 for normative data in girls aged <15 years. Uterine shape is denoted as infantile (I), cylindrical (C) or pubertal (P). * denotes patient with early true puberty.

| Age band (years) | Tanner breast stage | Uterine length (cm) | Uterine shape (I, C, P) | F:C ratio | ET mm | R ovary vol (mL) | R ovary n° follicles 2-10mm | L ovary vol (mL) | L ovary n° follicles 2-10mm |
|------------------|---------------------|---------------------|-------------------------|-----------|--------|------------------|----------------------------|----------------|--------------------------------|
| 2-4.9 (n=1)     | B1                  | 3.7                 | I                       | 0.6       | -      | 0.3              | ns                        | 0.3            | ns=1                             |
| 5-10.9 (n=6)    | B1 (n=5)            | 4                   | [3.5 - 4.6]             | 1.0       | [0.5 – 1.3] | 1 (n=1)           | 1.8                       | ns = 5          | 1.2 [0.2 – 3.3] ns = 3           |
|                 | B3 (n=1)            | n/a                 | P                       |           |        |                  |                           |                |                                  |
| 11-14.9 n=8     | B1 (n=3)            | 3.5, 4.3, 5         | C                       | 0.86      | [0.5 – 1.4] | 2.7 [0.8 – 7.6]  |                           | 2.5 [1.9 – 7.4] |                                  |
|                 | B2 (n=3)            | 3.5, 5, 5.1         | I,C,P                   | 0.51, 1.4 |        | 1 (n=1)          | 1.4, 7, 0.8              | ns, 0, 4       | 2.5, 2.6, 4.2 ns, 0, 5           |
|                 | B3 (n=2)            | 5.7, 5.8            | C                       | 0.86, 0.75|        | 7.6, nv         |                           | 3, nv           |                                  |
| 15-19.9 (n=10)  |                     |                     |                         |           |        |                  |                           |                |                                  |
|                 |                     |                     |                         |           |        |                  |                           |                |                                  |
| ≥20 (n=5)       |                     |                     |                         |           |        |                  |                           |                |                                  |

F:C ratio = fundo-cervical ratio. ET = endometrial thickness. R= right, L = left ovary. nv = ovary not visualised. ns = not seen. n/a = not available
Table 4. Biochemical findings in 25 of 37 female patients with Prader-Willi syndrome, showing one point per patient per age band. Median (range) values are given, patient number (n=). * = excludes one patient with early puberty aged 9.8 years (see text).

| Age band (years) | Basal LH U/L [<0.2 – 1.8] n=6 | Peak LH U/L [<0.2 – 5.8] n=4 | Basal FSH U/L [0.6 – 11.4] n=6 | Peak FSH U/L [9.6 – 51.2] n=3 | Estradiol pmol/L [<0.2 – 7] (ud=0) |
|------------------|--------------------------------|-----------------------------|-------------------------------|--------------------------------|----------------------------------|
| 2-4.9            | 0.3                            | 1.4                         | 1.6                           | 13.3                           | 120 [70-180] (n=6)               |
|                  | [0.2 - 1.8]                    | [0.2 – 5.8]                 | [0.6 – 11.4]                 | [9.6 – 51.2]                   |                                  |
| 5-10.9           | 0.2                            | 1.8*                        | 0.9                           | 6.4 [4.1 -14.4]                | [50,99] (n=2)                    |
|                  | [0.2 – 4.2]                    | [0.5 – 2.9]                 | [<0.2 – 7.2]                  | [4.1 -14.4]                    |                                  |
| 11-14.9          | 0.5 [0.2 – 4.7]                | 6.2                         | 2.3                           | 15.0                           | 167 [115 – 520] (n=6)            |
|                  | n=10                           | [0.2 – 9.3]                 | [<0.2 – 5.1]                  | [0.8 – 21.3]                   |                                  |
| 15-19.9          | 1.6 [0.2 – 5.2]                | 11.9                        | 4.8                           | 14.2                           | 176 [115 – 520] (n=6)            |
|                  | n=9                            | [2.4 – 35.4]                | [0.4 – 8.2]                   | [6.2 – 19.4]                   |                                  |
| ≥20              | 3.1 (2.32)                     | 4.1, 25.4                   | 6.0                           | 6.2, 14.1                      | 95 [70-180] (n=7)                |
|                  | 2.75 [0.2 – 7]                 | [0.5 – 14.1]                | [6.2, 14.1]                   |                                 |                                  |
|                  | n=2                            | n=8                         | n=2                           |                                 |                                  |

LH = luteinising hormone, FSH = follicle stimulating hormone, ud = undetectable.
Table 5. Biochemical findings 38 of 56 male patients with Prader-Willi syndrome, showing one point per patient per age band. Median (range) values are shown. Testosterone values post hCG given to 16/19 patients prior to surgery and to 9 patients to test Leydig cell reserve are shown. Data does not include patients on testosterone therapy. * = after excluding anorchic patient with LH 19.2 and FSH 65.2 U/L

| Age Band | Basal LH U/L | Peak LH U/L | Basal FSH U/L | Peak FSH U/L | Basal T nmol/L | Post hCG T nmol/L | Inhibin B pg/mL |
|----------|--------------|-------------|--------------|--------------|----------------|------------------|----------------|
| 0-1.9    | 0.2[<0.2 - 2.8] n=7 | 15.1[0.6 - 46.9] n=6 | 1.3[<0.2 - 4.0] n=7 | 12.4[2.6 – 16.7] n=6 | 0.9[0.4 - 2.4] n=4 | 24.9[5.7 – 41.5] n=6 | |
| 2-4.9    | 0.2[<0.2 – 0.5] n=5 | 1.0,1.2 n=2 | 0.2[<0.2 – 1.7] n=5 | [5, 13.5] n=2 | 0.35[0.3 – 0.7] n=6 | 12.0 n=1 | 13.3, 23.8 n=2 |
| 5-10.9   | 0.2[<0.2 – 1.9] n=13 | 1.45[<0.2 – 5.4] n=10 | 0.4[<0.2 -2.3] n=10 | 4.5[2.1 – 9.3] n=10 | 0.5[0.3– 0.7] n=10 | 3.35[1.0– 20.4] n=6 | 70 n=1 |
| 11-14.9  | 0.3[<0.2 – 5.0] n=15 | 4.1[<0.2 – 20.9] n=13 | 3.6[<0.2 – 20.9] n=13 | 3.7[1.6 – 23] n=6 | 2.0[0.3 – 8.4] n=13 | 8.3[7.7 – 26.8] n=5 | 14.7, 22.7, 59.8 n=3 |
| 15-19.9  | 1.3 (2.1) 0.85[<0.2 – 7.4] n=18 | 17.0(25.7) 10.1[<0.2 – 27.7] n=18 | 8.53 (8.0) 7.6[<0.2 – 27.7] n=18 | 14.3 (17.6) 11.4[<0.2 – 53.9] n=9 | 2.8 (2.6) 1.8 [0.3 – 10.8] n=18 | 5.4 (5.47) 3.2 [0.8 – 12.8] n=6 | 12.1, 11.1, 28.2, 67.3 n=4 |
| ≥20      | 1.6 (1.56) 1.6 [<0.2 – 4.1] n=9* | 0.2, 0.2 n=2 | 7.8 (9.1) 6.9 [<0.2 – 27.1] n=9* | 0.2, 0.5 n=2 | 2.7 (2.1) 1.7 [0.5 – 6.5] n=10 | 1.4 n=1 | 17.2,19.6, 35.1, 35.4, 44.4 n=5 |

LH = luteinising hormone, FSH = follicle-stimulating hormone, T = testosterone, hCG = human chorionic gonadotrophin
### Initial Testicular Position

| Condition                         | Count |
|----------------------------------|-------|
| Bilateral Cryptorchidism         | 44    |
| Unilateral Cryptorchidism        | 9     |
| Normally Descended               | 2     |

### Testicular Position After Prolonged hCG

- Total n= 56
- Bilateral Cryptorchidism: 44 - 3 = 41
- Unilateral Cryptorchidism: 9 + 2 = 11
- Normally Descended: 2 + 1 = 3

### Outcome of Surgery (if performed)

(n = aged < 11 yrs at last review)

| Procedure | n=1 | N/K | n=1 | Never | n=6 (2) | U | n=5 | P | n=8 (3) | S | n=21 (9) |
|-----------|-----|-----|-----|-------|---------|---|-----|---|---------|---|----------|
| Orch      | 1   |     |     | 2     |         |   | 5   | 1 |         |   | 21 (9)   |
| U         | 2   |     |     |       |         |   |     |   |         |   |          |
| S         | 8   |     |     |       |         |   |     |   |         |   |          |

### Max Spontaneous Genital Stage ≥11yr (Testicular Volume)

| Stage | G1 | G2 | G3 | G4 | G5 |
|-------|----|----|----|----|----|
|       | 1  | 4  | 5  | 1  | 1  |
|       | 1  | 4  | 5  | 1  | 1  |
|       | 1  | 4  | 5  | 1  | 1  |
|       | 1  | 4  | 5  | 1  | 1  |
|       | 1  | 4  | 5  | 1  | 1  |

### Testosterone Treatment (Initial) Aged >13 Years

| Route | Dose (mg) | Frequency | Count |
|-------|-----------|-----------|-------|
| I.M.  | 50-62.5   | 4W        | 1     |
|       | 6W        |           | 1     |
|       | 100       | 4W        | 2     |
|       | 6W        |           | 1     |
| Oral  | 40        | Daily     | 2     |
| I.M.  | 1000      | 3M        | 1     |

Copyright © 2019 the authors
